Discover How Fremanezumab Can Help with Migraines

Credibility

Interest

Key Takeaway

Fremanezumab can significantly reduce the number of migraine days for many people over a long period.

What They Found

In a study with over 1,100 patients, more than half experienced a big drop in the number of migraine days after using fremanezumab for 6 months. This means if someone had 10 migraine days a month, they might have only 4 or 5 after treatment. The study also showed that people needed less medicine to help with their migraines, which is great since taking fewer pills can be easier. Additionally, patients reported feeling less disabled by their migraines, meaning they could do more of their daily activities. Overall, fremanezumab showed it’s effective and safe for long-term use in preventing migraines.

Who Should Care and Why

This information is important for MS patients who also struggle with migraines, as managing both conditions can be challenging. Caregivers will benefit too, as understanding these options can help them support their loved ones better. Knowing that a treatment can reduce migraine days can improve quality of life, just like finding a tool that makes a difficult task easier. Healthcare providers can use these findings to recommend effective treatments, helping patients feel more in control of their symptoms. Ultimately, this research highlights a promising option for those dealing with the added burden of migraines on top of MS.

Important Considerations

It's important to note that the study focused only on patients who had already been using fremanezumab for at least 6 months, so it may not reflect results for new patients. The findings are based on real-world experiences, which are valuable but can vary from person to person. Finally, while no new safety concerns were found, every patient may react differently to medications, so close monitoring is always recommended.

Categories:

Treatment Updates Living with MS Nutrition

Article Topics:

Calcitonin gene-related peptideChronicEpisodicMigraineReal-world dataReal-world evidence

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News